Page 4 - மூத்தவர் பாதுகாப்பற்றது குறிப்புகள் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

•Reaffirms 2021 Full Year Forecast for Revenues and Profit GAITHERSBURG, Md., July 29, 2021-Emergent BioSolutions Inc. (NYSE: EBS) today reported financial results for the second quarter ended June 30, 2021. Our second quarter performance demonstrates the strength of our strategy and diversified business model, said Robert G. Kramer, president and chief executive officer of Emergent BioSolutions. Through continued investment and innovation, we will play an important role in helping deliver solutions to the public health threats we face. We are proud to be resuming production of COVID-19 vaccine batches following additional reviews and collaboration with the Food and Drug Administration and our manufacturing partner.

United statesRobert burrowsRobertg kramerMatt hartwigBaltimore bayviewContract developmentEmergent biosolutions incAgency for medicinesCompany bayviewDevelopment expensesDepartment of healthCompany rockvilleReconciliation of net researchPublic health agency canadaBiomedical advanced researchHuman services